[go: up one dir, main page]

ES2192988B1 - Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas. - Google Patents

Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.

Info

Publication number
ES2192988B1
ES2192988B1 ES200200496A ES200200496A ES2192988B1 ES 2192988 B1 ES2192988 B1 ES 2192988B1 ES 200200496 A ES200200496 A ES 200200496A ES 200200496 A ES200200496 A ES 200200496A ES 2192988 B1 ES2192988 B1 ES 2192988B1
Authority
ES
Spain
Prior art keywords
dermatology
statins
new applications
pharmaceutical formulations
corresponding pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200200496A
Other languages
English (en)
Other versions
ES2192988A1 (es
Inventor
Jose Manuel Quesada Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES200200496A priority Critical patent/ES2192988B1/es
Priority to PCT/ES2003/000094 priority patent/WO2003072013A2/es
Publication of ES2192988A1 publication Critical patent/ES2192988A1/es
Application granted granted Critical
Publication of ES2192988B1 publication Critical patent/ES2192988B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nuevas aplicaciones de las estatinas en dermatología y las correspondientes formulaciones farmacéuticas.
Dichas aplicaciones están dirigidas a la fabricación de una formulación farmacéutica para el tratamiento de la psoriasis en sus diversas formas y grados de gravedad, de importante repercusión en el sector médico-farmacéutico.
La referida formulación incorpora una estatina, una superestatina o un derivado farmacéuticamente aceptable de las mismas como componente principal, pudiendo contener adicionalmente calcitriol y/o coenzima Q.
ES200200496A 2002-02-28 2002-02-28 Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas. Expired - Fee Related ES2192988B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200200496A ES2192988B1 (es) 2002-02-28 2002-02-28 Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
PCT/ES2003/000094 WO2003072013A2 (es) 2002-02-28 2003-02-28 Nuevas aplicaciones de las estatinas en dermatología y las correspondientes formulaciones farmacéuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200496A ES2192988B1 (es) 2002-02-28 2002-02-28 Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.

Publications (2)

Publication Number Publication Date
ES2192988A1 ES2192988A1 (es) 2003-10-16
ES2192988B1 true ES2192988B1 (es) 2005-02-16

Family

ID=27763512

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200496A Expired - Fee Related ES2192988B1 (es) 2002-02-28 2002-02-28 Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.

Country Status (2)

Country Link
ES (1) ES2192988B1 (es)
WO (1) WO2003072013A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534459A (ja) 2006-04-26 2009-09-24 ローズモント・フアーマシユーテイカルズ・リミテツド 液体経口組成物
GB201814036D0 (en) 2018-08-29 2018-10-10 Ucl Business Plc New therapy
EP4003317B1 (en) 2019-07-29 2023-09-20 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
CN110368358B (zh) * 2019-09-02 2023-04-07 上海交通大学医学院附属新华医院 一种辛伐他汀的外用制剂及其应用
GB201918752D0 (en) * 2019-12-18 2020-01-29 Ucl Business Plc New therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
EP1390030A1 (en) * 2001-05-31 2004-02-25 Cellegy Pharmaceuticals, Inc Store operated calcium influx inhibitors and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEITZ-SCHMIDT, G. et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine, 2001, Vol. 7, páginas 687-692. Resumen; tabla 1. *

Also Published As

Publication number Publication date
ES2192988A1 (es) 2003-10-16
WO2003072013A3 (es) 2003-12-04
WO2003072013A2 (es) 2003-09-04

Similar Documents

Publication Publication Date Title
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
CY1122349T1 (el) Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ATE401875T1 (de) Pharmazeutische feste dispersionen von modafinil- verbindungen
LTPA2013018I1 (lt) 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas
CY1106130T1 (el) Παραγωγα 2-πυριδονης ως αναστολεις της ουδετepοφιλης ελαστασης
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
UY27882A1 (es) Compuestos quimicos
NO20073259L (no) Nye 4-arylaminopyndondenvater som MEK inhibrtorer av hyperproliferende lidelser
BR0306922A (pt) N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
TW200700392A (en) Novel compounds
UY29614A1 (es) Compuestos químicos
SE0101932D0 (sv) Pharmaceutical combinations
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
ES2192988B1 (es) Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
EP4342900C0 (en) SESQUITERPENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
CL2003002292A1 (es) Composicion farmaceutica que comprende un compuesto derivado de acido carboxilico, uno o mas compuestos terapeuticamente activos y un diluyente farmacologicamente aceptable; y su uso para tratar una enfermedad inflamatoria.
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
ITPR20020027A1 (it) Ampolla nebulizzatrice, in particolare per aerosolterapia.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031016

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192988B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180808